Repligen | RGEN - Gross Profit On Sales



Repligen reported $91.14M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Agilent USD 888M 22M Jul/2025
Align Technology USD 708.12M 28.01M Jun/2025
Bio Techne USD 198.81M 15.74M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Bruker USD 357.9M 33.3M Jun/2025
Charles River Laboratories USD 291.68M 48.42M Jun/2025
Danaher USD 3.52B 3M Jun/2025
Dentsply International USD 490M 24M Jun/2025
Exact Sciences USD 562.45M 61.91M Jun/2025
General Electric Aerospace USD 4.02B 286M Jun/2025
Henry Schein USD 952M 48M Jun/2025
Illumina USD 695M 12M Jun/2025
IQVIA Holdings USD 1.05B 251M Jun/2025
Mettler Toledo International USD 579.88M 54M Jun/2025
Myriad Genetics USD 134.2M 16.7M Mar/2025
Pfizer USD 10.88B 248M Jun/2025
Repligen USD 91.14M 385K Jun/2025
Revvity USD 392.56M 17.01M Jun/2025
Standard Biotools USD 10.63M 11.28M Jun/2025
Thermo Fisher Scientific USD 4.05B 260M Jun/2025
Waters USD 438.02M 53.06M Jun/2025
West Pharmaceutical Services USD 273.9M 42M Jun/2025